Dra. Desamparados Roda Pérez

Investigador Emergente
Grupo de Investigación en cáncer colorrectal y nuevos desarrollos terapéuticos en tumores sólidos

Presentación

Investigador
Emergente
Dra. Desamparados Roda Pérez

droda@incliva.es

Publicaciones
Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervello C, Garces-Albir M, Cervantes A, Ibarrola-Villava M. Cancers. 2021 Feb 27;13(5):994. doi: 10.3390/cancers13050994. PMID: 33673558

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. Tarazona Llavero N, Gimeno Valiente F, Gambardella V, Huerta Alvaro M, Roselló Keränen S, Zúñiga Trejos S, Calon A, Carbonell Asins J, Fontana E, Martínez Ciarpaglini M, Eason K, Rentero Garrido P, Fleitas Kanonnikoff T, Papaccio F, Moro Valdezate D, Nyamundanda G, Castillo Aliaga J, Espí Macias A, Sadanandam A, Roda Perez D, Cervantes Ruiperez A. Esmo Open. 2020 Sep;5(5):e000847. doi: 10.1136/esmoopen-2020-000847. PMID: 32967918

EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. Gimeno Valiente F, Riffo Campos Á, Ayala Gallego G, Tarazona Llavero N, Gambardella V, Rodriguez F, Huerta Alvaro M, Martínez Ciarpaglini M, Monton Bueno J, Roselló Keränen S, Roda Perez D, Cervantes Ruiperez A, Franco Vera L, Lopez Rodas G, Castillo Aliaga J. Scientific Reports. 2020 Feb 28;10(1):3723. doi: 10.1038/s41598-020-60476-7. PMID: 32111877

In the literature: April 2020. Gambardella V, Roda D, Tarazona N, Cervantes A. Esmo Open. 2020 Apr;5(2):e000749. doi: 10.1136/esmoopen-2020-000749. PMID: 32317263

In the literature: February 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. 2020 Feb;5(1):e000680. doi: 10.1136/esmoopen-2020-000680. PMID: 32079625

In the literature: June 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. Esmo Open. 2020 Jul;5(4):e000832. doi: 10.1136/esmoopen-2020-000832. PMID: 32641355

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Guo C, Chenard-Poiriet M, Roda D, de Miguel M, Harris S, Candilejo I, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner A, Carreira S, Riisnaes R, Finneran L, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez J, Minchom A, de Bono J, Banerji U. The Lancet Oncology. 2020 Nov;21(11):1478-1488. doi: 10.1016/S1470-2045(20)30464-2. PMID: 33128873

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. Papaccio F, Rosello S, Huerta M, Gambardella V, Tarazona N, Fleitas T, Roda D, Cervantes A. Cancers. 2020 Dec 3;12(12):E3611. doi: 10.3390/cancers12123611. PMID: 33287114

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Rosello S, Pizzo C, Huerta M, Munoz E, Aliaga R, Vera A, Alfaro-Cervello C, Jorda E, Garces-Albir M, Roda D, Dorcaratto D, Tarazona N, Torondel S, Guijarro J, Sanchiz V, Gambardella V, Fleitas-Kanonnikoff T, Lluch P, Pascual I, Ferrandez A, Sabater L, Cervantes A. Esmo Open. 2020 Nov;5(6):e000929. doi: 10.1136/esmoopen-2020-000929. PMID: 33229503

New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: 10.1016/j.annonc.2020.07.012. PMID: 32710931

Personalized Medicine: Recent Progress in Cancer Therapy. Gambardella V, Tarazona Llavero N, Cejalvo Andujar J, Lombardi P, Huerta Alvaro M, Roselló Keränen S, Fleitas Kanonnikoff T, Roda Perez D, Cervantes Ruiperez A. Cancers. 2020 Apr 19;12(4):1009. doi: 10.3390/cancers12041009. PMID: 32325878

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. Yap T, Kristeleit R, Michalarea V, Pettitt S, Lim J, Carreira S, Roda Perez D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner N, Ruddle R, Raynaud F, Decordova S, Swales K, Finneran L, Hall E, Rugman P, Lindemann J, Foxley A, Lord C, Banerji U, Plummer R, Basu B, Lopez J, Drew Y, de Bono J.Cancer Discovery. 2020 Oct;10(10):1528-1543. doi: 10.1158/2159-8290.CD-20-0163.PMID: 32532747

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. Gambardella V, Fleitas Kanonnikoff T, Tarazona Llavero N, Papaccio F, Huerta Alvaro M, Roselló Keränen S, Gimeno Valiente F, Roda Perez D, Cervantes Ruiperez A. Journal of Clinical Medicine. 2020 Sep 22;9(9):3049. doi: 10.3390/jcm9093049. PMID: 32971757

The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Gambardella V, Castillo Aliaga J, Tarazona Llavero N, Gimeno Valiente F, Martínez Ciarpaglini M, Cabeza Segura M, Roselló Keränen S, Roda Perez D, Huerta Alvaro M, Cervantes Ruiperez A, Fleitas Kanonnikoff T. Cancer Treatment Reviews. 2020 Jun;86:102015. doi: 10.1016/j.ctrv.2020.102015. PMID: 32248000

Trifluridine/Tipiracil in earlier lines of chemotherapy for advanced colorectal cancer. Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Sep;31(9):1097-1098. doi: 10.1016/j.annonc.2020.05.030. PMID: 32544547

Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. Martínez Ciarpaglini M, Fleitas Kanonnikoff T, Gambardella V, Llorca Cardeñosa M, Mongort Sanchis M, Mengual Fenollar R, Nieto G, Navarro Cerveró L, Huerta Alvaro M, Roselló Keränen S, Roda Perez D, Tarazona Llavero N, Navarro Fos S, Ribas Despuig G, Cervantes Ruiperez A. Esmo Open. 2019 May 27;4(3):e000470. doi: 10.1136/esmoopen-2018-000470. PMID: 31231566

Improving tumor budding evaluation in colon cancer by extending the assessment area in colectomy specimen. Martinez-Ciarpaglini C, Fernandez-Sellers C, Tarazona N, Roselló S, Huerta M, Roda D, Mongort C, Ferrández A, Navarro S, Cervantes A. Histopathology. 2019 Oct;75(4):517-525. doi: 10.1111/his.13900. PMID: 31081121

Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. Martinez-Ciarpaglini C, Oltra S, Roselló S, Roda D, Mongort C, Carrasco F, Gonzalez J, Santonja F, Tarazona N, Huerta M, Espí A, Ribas G, Ferrández A, Navarro S, Cervantes A. Modern Pathology. 2019 Feb;32(2):306-313. doi: 10.1038/s41379-018-0124-5. PMID: 30206410

NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2 -Amplified Gastric Cancer. Gambardella V, Gimeno-Valiente F, Tarazona N, Martinez-Ciarpaglini C, Roda D, Fleitas T, Tolosa P, Cejalvo JM, Huerta M, Roselló S, Castillo J, Cervantes A. Clinical Cancer Research. 2019 Mar 1;25(5):1639-1649. doi: 10.1158/1078-0432.CCR-18-242. PMID: 30504425

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, Roselló S, Martinez-Ciarpaglini C, Carbonell-Asins JA, Carrasco F, Ferrer-Martínez A, Bruixola G, Fleitas T, Martín J, Tébar-Martínez R, Moro D, Castillo J, Espí A, Roda D, Cervantes A. Annals of Oncology. 2019 Nov 1;30(11):1804-1812. doi: 10.1093/annonc/mdz390. PMID: 31562764

Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma. Gambardella V, Fleitas T, Tarazona N, Cejalvo JM, Gimeno-Valiente F, Martinez-Ciarpaglini C, Huerta M, Roselló S, Castillo J, Roda D, Cervantes A. Annals of Oncology. 2019 Aug 1;30(8):1254-1264. doi: 10.1093/annonc/mdz143. PMID: 31046106

Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations. Roda D, Roselló S, Cervantes A. Annals of Oncology. 2019 Sep 1;30(9):1409-1410. doi: 10.1093/annonc/mdz229. PMID: 31350557

ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer. Gimeno-Valiente F, Riffo-Campos ÁL, Vallet-Sánchez A, Siscar-Lewin S, Gambardella V, Tarazona N, Cervantes A, Franco L, Castillo J, López-Rodas G. Scientific Reports. 2019 Jun 27;9(1):9339. doi: 10.1038/s41598-019-45411-9. PMID: 31249328

Proyectos
Referencia: PI18/01909
Título: Medicina personalizada en pacientes con cáncer colorrectal localizado: abordaje multiómico de la Enfermedad Mínima Residual en biopsia líquida y modelos de organoides
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Andrés Cervantes Ruipérez, Desamparados Roda
Duración: 2019 – 2021
Presupuesto: 141.570 €

+ Información
New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: 10.1016/j.annonc.2020.07.012. PMID: 32710931